1. CYP Update

2. BangladeshEthiopiaGhanaGuatemalaKenyaIndiaUgandaMadagascarNepalNigeria Oral Contraceptives√√13√√√√√√√ Condoms√√√√√√√240√√ Female Condoms√√√√√√√√ Vaginal Foaming Tabs√√√√√√√ Depo Provera Inject.√√√√√√√√√√ Noristerat Injectable√√√√√√√ Cyclofem 1-Mnth Inject.√√√√√√√ Copper-T 380-A IUD√√√√√√√√√√ Norplant Implant√√√√√√√√√ Implanon Implant√√√2.8√√3.5√ Jadelle Implant√√√√2.8√√√√√ FAM (eg SDM)√√√√√1.73√ LAM√√√√√√√√ SterilizationR√√RRRR√RR ECPs √√√√√√ 20 P-only 8 combined pill.375 PSI √ Reporting from USAID Missions on CYP Conversion Factors √ = uses USAID conversion factors R = uses USAID regional default values Blank = does not report on that method

3. Principles for CYP Conversion Factor Development, USAID 2011 Seen only as an update Keep simple for calculations Strive for uniformity across countries etc. Base on most realistic programmatic data Meaningfully related to unintended pregnancies averted, (but not actual measurement of unintended pregnancies averted.) Recognize these are only approximations – avoid false precision Recognize “intangibles” exist (e.g. dual method use, extended effectiveness of injectables) Kind of a “coverage” indicator – level playing field of credit

4. Other objectives not addressed by CYP Quality - including choice Continuation Actual impact on unintended pregnancy

7. Thank you